CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company's ...
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Moderna said Wednesday afternoon that its ...
Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Topline results were announced from a phase 3 study evaluating Moderna’s ...
Long before the Zika virus became a global fear, cytomegalovirus, or CMV, was commonly infecting developing fetuses and causing many of the same brain and developmental impairments. The virus, one of ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results